Silas Inman

New York, United States

Senior Vice President, Content at CURE Magazine

Senior Vice President, Content at Pharmacy Times

Senior Vice President, Content at OncLive

SVP, Content @MJHLifeSciences. Focused on creating innovative, expert-driven content @OncLive @MedEconomics @AJMC_Journal @Pharmacy_Times @MDMagazine plus more

Articles

Multiple Myeloma Treatment: The Price of Success

1 week ago | managedhealthcareexecutive.com | Silas Inman

May 5, 2025MHE PublicationMHE May 2025The multiple myeloma armamentarium is large and getting larger. That makes treatment choices complex and the cost of treatment high. Editor's note: This is expanded version of an article that was posted as part of coverage of the 2025AMCP Annual Meeting. The treatment of multiple myeloma is often described as complicated or complex.
GLP-1 Side Effects Have a Side Effect on Pharmacy Costs| AMCP Annual 2025

1 month ago | managedhealthcareexecutive.com | Silas Inman

Glucagon-like peptide 1 (GLP-1) treatment resulted in side effects that often required additional medications, increasing overall pharmacy use and costs among GLP-1 drugs compared with nonusers, according to a real-world claims analysis completed by Blue Cross Blue Shield Association (BCBSA) and Blue Health Intelligence (BHI) that was presented as a poster at the annual meeting of the Academy of Managed Care Pharmacy in Houston this week When excluding the costs of the GLP-1 drugs themselves,...
Multiple Myeloma Treatment Is a Success Story. The Price Is Complex Treatment Decisions - and Cost | AMCP Annual 2025

1 month ago | managedhealthcareexecutive.com | Silas Inman

The most used words to describe the treatment paradigm for patients with multiple myeloma were complicated and complex, according to a poll during a session on managing multiple myeloma at the annual meeting of the Academy of Managed Care Pharmacy (AMCP) in Houston. The complexity comes from a wealth of highly effective, multidrug regimens that have gained FDA approval in a relatively short amount of time.
HER2 Therapies Redefine Brain Metastasis Treatment in Breast Cancer

2 months ago | targetedonc.com | Silas Inman

The remarkable intracranial efficacy of novel HER2-targeted therapies has established a new treatment paradigm, allowing oncologists to prioritize systemic therapies over local interventions for managing small, asymptomatic brain metastases in patients with metastatic breast cancer, noted Sara A.
Advancing Treatments for ET and CDK4/6 Resistance in HR+ Breast Cancer

2 months ago | targetedonc.com | Silas Inman

Multiple novel agents with diverse mechanisms of action are currently in development to overcome resistance to endocrine therapy (ET) and CDK4/6 inhibitors in hormone receptor–positive breast cancer. This ongoing research, highlighted in a session by Hope S. Rugo, MD, at the 42nd Annual Miami Breast Cancer Conference, aims to address the significant unmet clinical need in this patient population.1“We stand here at the brink of a precipice.
SERDs, PROTAC, and CERANs Offer Hope Following ET/CDK4/6 Inhibitor Resistance in Breast Cancer

2 months ago | onclive.com | Silas Inman

Several promising new agents are currently in development across various mechanisms of action to address the unmet need resulting from resistance to the combination of endocrine therapy (ET) and CDK4/6 inhibition for patients with hormone receptor–positive breast cancer, according to a session by Hope S. Rugo, MD, at the 42nd Annual Miami Breast Cancer Conference.1“We stand here at the brink of a precipice. There’s going to be a whole lot of these drugs approved in the future.
Systemic Therapies Are Now Preferred in Some Patients With HER2+ Breast Cancer Brain Metastases

2 months ago | onclive.com | Silas Inman

The high level of intracranial activity seen with novel HER2-targeted therapies has created a new paradigm that defers local therapy in favor of systemic options to treat small asymptomatic brain metastases in patients with metastatic breast cancer, explained Sara A.
Socioeconomic Factors Impact Access to Allogeneic Stem Cell Transplant in AML

Dec 11, 2024 | targetedonc.com | Silas Inman

A multicenter study presented at the 2024 ASH Annual Meeting found that socioeconomic factors significantly impact access to allogeneic hematopoietic stem cell transplant (allo-HCT) in patients with acute myeloid leukemia (AML), with certain groups less likely to receive this potentially lifesaving treatment. Results from the study revealed that level of education, reliance on government assistance programs, and poverty level were associated with receipt of allo-HCT and outcomes.
Sonrotoclax/Zanubrutinib Combo Elicits Deep Responses for Untreated CLL/SLL

Dec 10, 2024 | cancernetwork.com | Silas Inman

Frontline treatment with sonrotoclax (BGB-11417) plus zanubrutinib (Brukinsa) elicited high responses with a tolerable safety profile patients with treatment-naïve chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), according to data from the phase 1/1b BGB-11417-101 study (NCT04277637) presented at the 2024 American Society of Hematology Annual Meeting & Exposition (ASH).1 At week 48, the combination of standard dose zanubrutinib plus 160 mg or 320 mg sonrotoclax elicited an...
Superior Rates of MRD Upheld by Isatuximab Combo in Multiple Myeloma

Dec 10, 2024 | cancernetwork.com | Silas Inman

Data from the phase 3 IMROZ study (NCT03319667) presented at the 2024 American Society of Hematology Annual Meeting & Exposition (ASH) found that, for patients with transplant-ineligible newly diagnosed multiple myeloma, strong responses and positive rates of minimal residual disease (MRD) negativity were elicited by a treatment regimen of the CD38-directed monoclonal antibody isatuximab (Sarclisa) in combination with initial bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone...